{"gao_id": "GAO-20-251", "published": "2020-01-31T12:00:00Z", "released": "2020-01-31T07:00:00Z", "summary": "Drugs that treat certain tropical diseases, rare pediatric diseases and illnesses related to public health emergencies are essential\u2014but they may not be the most profitable to make. When drug developers make these kinds of drugs, FDA can award them \u201cpriority review vouchers.\u201d Drug developers can redeem a voucher to speed up FDA review of a future\u2014potentially more profitable\u2014drug. Vouchers can also be sold to other...", "title": "Drug Development: FDA's Priority Review Voucher Programs", "topics": ["Tuberculosis", "AIDS", "Pharmaceutical industry", "Health Care", "Medical countermeasures", "Smallpox", "Malaria", "User fees", "Pharmaceuticals", "Food", "Drug safety", "Press releases", "New drugs", "Biological products", "AIDS treatment", "Adults", "Clinical trials", "Financial instruments", "Diseases", "Drugs", "Pediatrics"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-20-251", "versions": [{"title": "Highlights Page (1 page)", "url": "https://www.gao.gov/assets/gao-20-251-highlights.pdf"}, {"title": "Full Report (43 pages)", "url": "https://www.gao.gov/assets/gao-20-251.pdf"}]}